Intraparenchymal and intratumoral interstitial infusion of anti-glioma monoclonal antibody 8H9

Neurosurgery

Volumn 63, Issue 6, 2008, Pages 1166-1174

  Luther, Neal ^a   Cheung, Nai Kong V ^b   Dunkel, Ira J ^b   Fraser, Justin F ^a   Edgar, Mark A ^b   Gutin, Philip H ^b   Souweidane, Mark M ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Antibody; Convection; Glioma; Immunotherapy; Interstitial

Indexed keywords

IMMUNOGLOBULIN G1 ANTIBODY; MONOCLONAL ANTIBODY 8H9; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; AUTOANALYSIS; CANCER INFILTRATION; CORPUS STRIATUM; DIFFUSION; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG INFUSION; DRUG TRANSPORT; FEEDING BEHAVIOR; GLIOBLASTOMA; HUMAN; HUMAN CELL; NONHUMAN; NUDE RAT; PRIORITY JOURNAL; RAT; THERMODYNAMICS; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; GLIOMA; HUMANS; INFUSIONS, INTRALESIONAL; METABOLIC CLEARANCE RATE; RATS; RATS, NUDE; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 58249115993     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000334052.60634.84     Document Type: Article

References (48)

1. Betz AL, Shakui P, Davidson BL: Gene transfer to rodent brain with recombinant adenoviral vectors: Effects of infusion parameters, infectious titer, and virus concentration on transduction volume. Exp Neurol 150:136-142, 1998.
2. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH: Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 91:2076-2080, 1994.
3. 2 fragment: Preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma. Nucl Med Biol 31:345-355, 2004.
4. Bruce JN, Falavigna A, Johnson JP, Hall JS, Birch BD, Yoon JT, Wu EX, Fine RL, Parsa AT: Intracerebral clysis in a rat glioma model. Neurosurgery 46:683-691, 2000.
5. Chen ZJ, Broaddus WC, Viswanathan RR, Raghavan R, Gillies GT: Intraparenchymal drug delivery via positive-pressure infusion: Experimental and modeling studies of poroelasticity in brain phantom gels. IEEE Trans Biomed Eng 49:85-96, 2002.
6. Chen MY, Hoffer A, Morrison PF, Hamilton JF, Hughes J, Schlageter KS, Lee J, Kelly BR, Oldfield EH: Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system. J Neurosurg 103:311-319, 2005.
7. Chen MY, Lonser RR, Morrison PF, Governale LS, Oldfield EH: Variables affecting convection-enhanced delivery to the striatum: A systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg 90:315-320, 1999.
8. Croteau D, Walbridge S, Morrison PF, Butman JA, Vortmeyer AO, Johnson D, Oldfield EH, Lonser RR: Real-time in vivo imaging of the convective distribution of a low-molecular-weight tracer. J Neurosurg 102:90-97, 2005.
9. Cunningham J, Oiwa Y, Nagy D, Podsakoff G, Colosi P, Bankiewicz KS: Distribution of AAV-TK following intracranial convection-enhanced delivery into rats. Cell Transplant 9:585-594, 2000.
10. Davis TA, White CA, Grillo-López AJ, Velásquez WS, Link B, Maloney DG, Dillman RO, Williams ME, Mohrbacher A, Weaver R, Dowden S, Levy R: Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab. J Clin Oncol 17:1851-1857, 1999.
11. Debinski W, Gibo DM, Hulet SW, Connor JR, Gillespie GY: Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res 5:985-990, 1999.
12. Degen J, Walbridge S, Vortmeyer AO, Oldfield EH, Lonser RR: Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats. J Neurosurg 99:893-898, 2003.
13. Fleming A, Saltzman WM: Pharmacokinetics of the carmustine implant. Clin Pharmacokinet 41:403-419, 2002.
14. 14C-sucrose delivery to the brain by intravenous, intraventricular, and convection-enhanced intracerebral infusion. J Neurosurg 90:321-331, 1999.
15. Hjortland GO, Garman-Vik SS, Juell S, Olsen OE, Hirschberg H, Fodstad O, Engebraaten O: Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme. J Neurosurg 100:320-327, 2004.
16. Kaiser MG, Parsa AT, Fine RL, Hall JS, Chakrabarti I, Bruce JN: Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery 47:1391-1399, 2000.
17. Kawakami K, Kawakami M, Kioi M, Husain SR, Puri RK: Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model. J Neurosurg 101:1004-1011, 2004.
18. Kondziolka D, Flickinger JC, Bissonette DJ, Bozik M, Lunsford LD: Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms. Neurosurgery 41:776-785, 1997.
19. 131I-8H9. Presented at the annual meeting of the American Association for Cancer Research, Los Angeles, April 14-18, 2007.
20. Kroll RA, Pagel MA, Muldoon LL, Roman-Goldstein S, Neuwelt EA: Increasing volume of distribution to the brain with interstitial infusion: Dose, rather than convection, might be the most important factor. Neurosurgery 38:746-754, 1996.
21. Kunwar S: Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: Presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl (Wien) 88:105-111, 2003.
22. Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD, Croteau DJ, Sherman JW, Puri RK; Cintredekin Besudotox Intraparenchymal Study Group: Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: A report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 25:837-844, 2007.
23. Laske DW, Morrison PF, Lieberman DM, Corthesy ME, Reynolds JC, Stewart-Henney PA, Koong SS, Cummins A, Paik CH, Oldfield EH: Chronic interstitial infusion of protein to primate brain: Determination of drug distribution and clearance with single-photon emission computerized tomography imaging. J Neurosurg 87:586-594, 1997.
24. Lidar Z, Mardor Y, Jonas T, Pfeffer R, Faibel M, Nass D, Hadani M, Ram Z: Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: A phase I/II clinical study. J Neurosurg 100:472-479, 2004.
25. Lieberman DM, Laske DW, Morrison PF, Bankiewicz KS, Oldfield EH: Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 82:1021-1029, 1995.
26. Lonser RR, Gogate N, Morrison PF, Wood JD, Oldfield EH: Direct convective delivery of macromolecules to the spinal cord. J Neurosurg 89:616-622, 1998.
27. Lonser RR, Walbridge S, Garmestani K, Butman JA, Walters HA, Vortmeyer AO, Morrison PF, Brechbiel MW, Oldfield EH: Successful and safe perfusion of the primate brainstem: In vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg 97:905-913, 2002.
28. Mardor Y, Rahav O, Zauberman Y, Lidar Z, Ocherashvilli A, Daniels D, Roth Y, Maier SE, Orenstein A, Ram Z: Convection-enhanced drug delivery: Increased efficacy and magnetic resonance image monitoring. Cancer Res 65:6858-6863, 2005.
29. Modak S, Kramer K, Gultekin SH, Guo HF, Cheung NK: Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Res 61:4048-4054, 2001.
30. Morrison PF, Laske DW, Bobo H, Oldfield EH, Dedrick RL: High-flow microinfusion: Tissue penetration and pharmacodynamics. Am J Physiol 266:R292-R305, 1994.
31. Nguyen TT, Pannu YS, Sung C, Dedrick RL, Walbridge S, Brechbiel MW, Garmestani K, Beitzel M, Yordanov A, Oldfield EH: Convective distribution of macromolecules in the primate brain demonstrated using computerized tomography and magnetic resonance imaging. J Neurosurg 98:584-590, 2003.
32. Nguyen JB, Sanchez-Pernaute R, Cunningham J, Bankiewicz KS: Convection-enhanced delivery of AAV-2 combined with heparin increases TK gene transfer in the rat brain. Neuroreport 12:1961-1964, 2001.
33. Occhiogrosso G, Edgar MA, Sandberg DI, Souweidane MM: Prolonged convection-enhanced delivery into the rat brainstem. Neurosurgery 52:388-394, 2003.
34. Olivi A, Grossman SA, Tatter S, Barker F, Judy K, Olsen J, Bruce J, Hilt D, Fisher J, Piantadosi S: Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: A New Approaches to Brain Tumor Therapy CNS Consortium Trial. J Clin Oncol 21:1845-1849, 2003.
35. Onda M, Wang QC, Guo HF, Cheung NK, Pastan I: In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma. Cancer Res 64:1419-1424, 2004.
36. Prados MD, Lang FF, Sherman JW, Strauss LC, Fleming CK, Aldape KD, Kunwar S, Yung WKA, Chang SM, Husain SR, Gutin PH, Raizer J, Piepmeier JM, Berger M, McDermott M, Puri RK: Convection-enhanced delivery (CED) by positive pressure infusion for intra-tumoral and pretumoral administration of IL13-PE38QQR: A recombinant rumor-targeted cytotoxin in recurrent malignant glioma. Neuro Oncol 4:S78, 2002 (abstr).
37. Press OW, Leonard JP, Coiffier B, Levy R, Timmerman J: Immunotherapy of Non-Hodgkin's lymphomas. Hematology Am Soc Hematol Educ Program 221-240, 2001.
38. Puri RK, Hoon DS, Leland P, Snoy P, Rand RW, Pastan I, Kreitman RJ: Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Cancer Res 56:5631-5637, 1996.
39. Raizer JJ, Malkin MG, Kleber M, Abrey LE: Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. Neuro Oncol 6:247-252, 2004.
40. Rand R, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK: Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 6:2157-2165, 2000.
41. Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, Friedman HS, Herndon JE 2nd, Kunwar S, Marcus S, McLendon RE, Paolino A, Penne K, Provenzale J, Quinn J, Reardon DA, Rich J, Stenzel T, Tourt-Uhlig S, Wikstrand C, Wong T, Williams R, Yuan F, Zalutsky MR, Pastan I: Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neuro Oncol 65:27-35, 2003.
42. Sampson JH, Akabani G, Friedman AH, Bigner D, Kunwar S, Berger MS, Bankiewicz KS: Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. Neurosurg Focus 20:E14, 2006.
43. Sandberg DI, Edgar MA, Souweidane MM: Convection-enhanced delivery into the rat brainstem. J Neurosurg 96:885-891, 2002.
44. Souweidane MM, Occhiogrosso G, Mark EB, Edgar MA, Dunkel IJ: Interstitial Infusion of carmustine in the rat brain stem with systemic administration of O6-benzylguanine. J Neurooncol 67:319-326, 2004.
45. 14C-sucrose in RG-2 rat gliomas after intravenous and convection-enhanced delivery. Neuro Oncol 6:104-112, 2004.
46. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel LA, Fisher RI: Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 19:389-397, 2001.
47. Wood JD, Lonser RR, Gogate N, Morrison PF, Oldfield EH: Convective delivery of macromolecules into the naive and traumatized spinal cords of rats. J Neurosurg 90:115-120, 1999.
48. Xu H, Cheung I, Cheung N: 4Ig-B7H3: A target for monoclonal antibody (MoAb) therapy of human solid tumors. Presented at the annual meeting of the American Association for Cancer Research, San Diego, April 12-16, 2008 (abstr).